An acellular pertussis vaccine in healthy adults: safety and immunogenicity. Pennridge Pediatric Associates

Autor:	E P, Rothstein, E L, Anderson, M D, Decker, G A, Poland, K S, Reisinger, M M, Blatter, R M, Jacobson, C A, Mink, D, Gennevois, A E, Izu, F, Sinangil, A G, Langenberg
Rok vydání:	1999
Předmět:	Adult Male Pertussis Vaccine Adolescent CHO Cells Middle Aged Antibodies Bacterial Injections Intramuscular Bordetella pertussis Placebos Double-Blind Method Pertussis Toxin Vaccines Inactivated Pregnancy Cricetinae Mutagenesis Site-Directed Animals Humans Female Virulence Factors Bordetella Aged
Zdroj:	Vaccine. 17(23-24)
ISSN:	0264-410X
Popis:	Recent data indicate that Bordetella pertussis can be an important cause of illness in adolescents and adults. In a randomized observer- and subject-blinded study, adults (or = 18 years of age) received an acellular pertussis (aP) vaccine containing genetically inactivated pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (PRN), or a saline placebo, and were monitored for safety and immunogenicity. IgG antibodies to PT, FHA, and PRN were measured by enzyme-linked immunosorbent assay (ELISA) and PT neutralization by a Chinese hamster ovary (CHO) cell assay. Local reactions, more common in the aP group, were mild and transient. One month after immunization, geometric mean ELISA antibody concentrations for the aP and placebo groups, respectively, were: anti-PT, 463 and 7.6; anti-FHA, 417 and 18; and anti-PRN, 855 and 14. The anti-PT neutralization titers for the aP and placebo groups were 1:3439 and 1:58 respectively. This aP vaccine is a safe and immunogenic candidate booster vaccine against pertussis for adults.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::23151eeb7eef2a2afa380054e9a8b1af https://pubmed.ncbi.nlm.nih.gov/10462235 Zobrazit plný text záznamu Full Text from ScienceDirect